Close menu




Biotech

Photo credits: pixabay.com

Commented by André Will-Laudien on August 23rd, 2021 | 12:25 CEST

BioNTech, Defence Therapeutics, Dermapharm, NanoRepro - Vaccinate, Test, Treat!

  • Biotechnology

The vaccination rate in Germany is now just under 59% with complete second vaccination. The Ministry of Health had assumed a 70-80% rate by late summer. The situation has now changed, and the autumn in Germany will likely take place under different conditions. Since the beginning of August, the many travelers returning home have had to undergo a test at the entry border to Germany. Presumably, the number of infections will also rise again, making testing mandatory for social life. Vaccination and testing, therefore, remain ongoing issues for the capital markets.

Read

Commented by André Will-Laudien on August 18th, 2021 | 10:43 CEST

Bayer, Cardiol Therapeutics, CureVac: The Champions League of Bio-Pharma!

  • Biotechnology

Biopharmaceutics is the first port of call in the fight against a wide range of diseases. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. Biological effectiveness results from the entry of the drug into the diseased organism, its distribution in tissues, and the chemical reaction called metabolism. When dealing with recent pandemics, good advice is expensive, and research into pharmaceuticals costs billions. When an active ingredient is found and registered, the patent clock starts ticking for the inventor. As a result, the hope of the biopharmaceutical company is to remain the sole provider in their healing segment for as long as possible.

Read

Commented by Armin Schulz on August 16th, 2021 | 13:27 CEST

BioNTech, XPhyto Therapeutics, Siemens Healthineers - Corona has triggered a boom

  • Biotechnology

While many companies have suffered greatly from the Corona pandemic, there are also a number of winners. First and foremost, vaccine manufacturers but also diagnostics companies experienced substantial growth rates in sales. Irrespective of Corona, it is increasingly crucial for the healthcare sector to push ahead with digitization, especially in diagnostics. Here, digitization offers the opportunity to significantly increase the quality and speed of diagnoses through artificial intelligence. Time, in particular, is an important factor here. Today, we take a closer look at three beneficiaries of the Corona Crisis.

Read

Commented by Carsten Mainitz on August 16th, 2021 | 11:20 CEST

Defence Therapeutics, Moderna, Evotec - Bet on the front-runners!

  • Biotechnology

Health is our most important asset. Biotech companies that protect it save not only human lives but also reap high profits. The price development of many biotech stocks over the past few months has been breathtaking. Investors are advised to focus on the frontrunners, as the market position gained as a first mover, the leadership position in a niche or innovative solution, will enable the companies to keep their competitors at bay for a long time to come.

Read

Commented by Fabian Lorenz on August 10th, 2021 | 11:57 CEST

Hot autumn for BioNTech, NanoRepro and XPhyto: Nothing works without testing and vaccination

  • Biotechnology

Shares of Corona vaccine and test manufacturers are in for a hot fall. Summer is drawing to a close, and the Delta variant is hard to stop. Calls for stricter measures are growing. Politicians are calling for vaccination premiums and mandatory testing for travelers returning home. The 1st FC Cologne recently announced that it would only allow vaccinated people into the stadium. BioNTech, NanoRepro and XPhyto are among the beneficiaries of this development. The latter Company could also benefit from demands from politicians. SPD health expert Karl Lauterbach called for mandatory "PCR" testing for unvaccinated people before visiting restaurants.

Read

Commented by André Will-Laudien on August 4th, 2021 | 11:23 CEST

MorphoSys, Defence Therapeutics, BioNTech, Pfizer - The next biotech explosion!

  • Biotechnology

Infectious diseases are diseases transmitted by pathogens such as bacteria, viruses or fungi. Depending on which organs and body parts they affect, they can cause very different symptoms. In Covid-19, we are dealing with a problematic initial situation because not every infected person has apparent symptoms at all. Moreover, the virus can also be transmitted from vaccinated individuals to the next host without any problems. That shows the high relevance of testing, despite increasing vaccination rates. On the one hand, the biotech sector is concerned with diagnostic procedures and, on the other hand, with suitable vaccinations to best prepare our immune system for the fight. In the current pandemic, the coming winter will also indicate the overall effectiveness of vaccines.

Read

Commented by André Will-Laudien on August 4th, 2021 | 11:10 CEST

XPhyto Therapeutics - Groundbreaking diagnostic platforms of the future

  • Biotechnology
  • Pharma

The number of infectious diseases that we humans are fighting today has increased significantly in recent decades, not just because they have become known and researched. Increasingly frequent variants and neoplasms have also led in turn to entirely new disease patterns. An important area upstream of the medical sector is the large diagnostics market. The umbrella term of diagnostics is used in particular in the context of the detection and differentiation of diseases. This is referred to as clinical diagnostics. Many test and diagnostic procedures are assigned to the bioscience sector since studies must first prove their exact validity. Worldwide, more than 10,000 companies are involved in symptom research, the detection, screening and analysis of the diagnosis of diseases.

Read

Commented by Stefan Feulner on August 3rd, 2021 | 12:22 CEST

Siemens Healthineers, Cardiol Therapeutics, BioNTech - Tomorrow's blockbusters

  • Biotechnology

The fight against the coronavirus and the possible return to everyday life promises companies in the biotechnology sector billions in profits. At the forefront, vaccine producers such as BioNTech with its pharmaceutical partner Pfizer or Moderna are the primary beneficiaries of the pandemic. In addition, start-ups are emerging from the diagnostics and therapy sectors, whose formulations have blockbuster potential and could follow a similar path to the vaccine manufacturers in the coming years.

Read

Commented by Stefan Feulner on July 27th, 2021 | 13:01 CEST

BioNTech, XPhyto Therapeutics, MorphoSys - Here we go again

  • Biotechnology

The numbers of new SARS-CoV-2 infections in Germany are rising again, albeit still at a relatively low level. Due to the spread of the Delta variant, Health Minister Jens Spahn warns of incidences beyond the 800 mark as early as this fall. In addition to masking and spacing, the issues surrounding vaccines against the various mutations and regular, reliable testing are returning to the front pages of the news pages.

Read

Commented by Carsten Mainitz on July 26th, 2021 | 13:55 CEST

BioNTech, Cardiol Therapeutics, CureVac - What is next?

  • Biotechnology

Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?

Read